Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial.
Fiche publication
Date publication
juillet 2022
Journal
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BEN ABDELGHANI Meher, Pr GHIRINGHELLI François, Dr KIM Stephano, Pr BIBEAU Frédéric
Tous les auteurs :
Coutzac C, Bibeau F, Ben Abdelghani M, Aparicio T, Cohen R, Coquan E, Dubreuil O, Evesque L, Ghiringhelli F, Kim S, Lesourd S, Neuzillet C, Phelip JM, Piessen G, Rochigneux P, Samalin E, Soularue E, Touchefeu Y, Tougeron D, Zaanan A, de la Fouchardière C
Lien Pubmed
Résumé
Immune checkpoint inhibitors (ICI) targeting Programmed death-1 (PD-1) have shown their efficacy in advanced MSI/dMMR (microsatellite instability/deficient mismatch repair) tumors. The MSI/dMMR status predicts clinical response to ICI. The promising results evaluating ICI in localized MSI/dMMR tumors in neoadjuvant setting need to be confirmed in MSI/dMMR solid tumors. The aim of the IMHOTEP trial is to assess the efficacy of neoadjuvant anti-PD-1 treatment in MSI/dMMR tumors regarding the pathological complete response rate.
Mots clés
Colorectal cancer, Endometrial cancer, Gastric cancer, Immune checkpoint inhibitor, MSI/dMMR, Perioperative immunotherapy
Référence
Dig Liver Dis. 2022 07 27;: